Statistics from Altmetric.com
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy and the efficacy of immunosuppressive or immunomodulating treatments with corticosteroids, intravenous immunoglobulin and plasma exchange has been established.1 2 For patients refractory to these conventional therapies, other immunosuppressants such as cyclophosphamide, ciclosporin rituximab and tumour necrosis factor (TNF)-α antagonists have been trialed.3 4
Conversely, several studies have established that immunosuppressive agents may trigger the development of CIDP. Recent examples include CIDP induced by TNF-α antagonists such as infliximab and etanercept.5 Separately, therapy with the TNF-α antagonists for rheumatoid …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.